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Abstract
The expression of the human β-like globin genes follows a well-orchestrated developmental pattern, undergoing
two essential switches, the first one during the first weeks of gestation (ε to γ), and the second one during the
perinatal period (γ to β). The γ- to β-globin gene switching mechanism includes suppression of fetal (γ-globin, HbF)
and activation of adult (β-globin, HbA) globin gene transcription. In hereditary persistence of fetal hemoglobin
(HPFH), the γ-globin suppression mechanism is impaired leaving these individuals with unusual elevated levels of
fetal hemoglobin (HbF) in adulthood. Recently, the transcription factors KLF1 and BCL11A have been established as
master regulators of the γ- to β-globin switch. Previously, a genomic variant in the KLF1 gene, identified by linkage
analysis performed on twenty-seven members of a Maltese family, was found to be associated with HPFH.
However, variation in the levels of HbF among family members, and those from other reported families carrying
genetic variants in KLF1, suggests additional contributors to globin switching. ASF1B was downregulated in the
family members with HPFH. Here, we investigate the role of ASF1B in γ- to β-globin switching and erythropoiesis
in vivo. Mouse-human interspecies ASF1B protein identity is 91.6%. By means of knockdown functional assays in
human primary erythroid cultures and analysis of the erythroid lineage in Asf1b knockout mice, we provide
evidence that ASF1B is a novel contributor to steady-state erythroid differentiation, and while its loss affects the
balance of globin expression, it has no major role in hemoglobin switching.
Keywords: Dyserythropoiesis, Hemoglobin switching, Hereditary persistence of fetal hemoglobin (HPFH),
Thalassemia, Gene expression, Erythropoiesis, ASF1B, KLF1, BCL11A
Background
The expression of the β-like globin genes follows a well-
orchestrated developmental pattern, undergoing two es-
sential switches, the first one during the first weeks of ges-
tation (ε to γ), and the second one around birth (γ to β)
[1–4]. Therefore, fetal hemoglobin (HbF), composed of
two α-globin and two γ-globin chains, is the dominant
type of hemoglobin during the fetal stages of development.
Around birth, HbF is gradually replaced by adult
hemoglobin (HbA), consisting of two α-globin and two β-
globin chains. Already at 6months of age, the major
hemoglobin in the circulation is HbA [5]. However, re-
sidual amounts of HbF continue to be synthesized
throughout adult life, and the amounts vary considerably,
with the large majority of adults having less than 1% of
HbF. Our understanding of β-like globin transcriptional
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control is historically based on Mendelian models of in-
heritance of natural mutants. Indeed, a series of genetic
variants of the β-globin cluster have been discovered that
impair the fetal-to-adult hemoglobin switch, leading to
persistent γ-globin expression and elevated HbF through-
out adult life. This condition is termed hereditary persist-
ence of fetal hemoglobin (HPFH) [6]. There are two types
of HPFH variants in the β-globin locus: point mutations
in the promoter of the γ-globin genes (HBG1 or HBG2)
and deletions removing substantial regions of the β-globin
cluster, often including the β-globin gene (HBB) [7]. A
range of conditions characterized by HbF levels that do
not fit clear Mendelian inheritance models or the typical
HPFH phenotype, i.e., high HbF levels accompanied by
concomitant lower HbA2 (α2δ2) levels, have been previ-
ously reported. Although some of this variability can be
explained by the β-globin cluster haplotype, a substantial
proportion of the HbF increase is not linked to the β-
globin cluster, suggesting multi-factorial genetic players in
the fine-tuning of β-like globin gene expression
regulation.
It is now evident that common HbF variation is a quan-
titative genetic trait, shaped by common polymorphisms
in genes that are not related to the human β-like globin
gene cluster. There are only a few examples of such SNPs
in genes, affecting for example BCL11A (MIM 606557)
residing on chromosome 2 [8–11] and the intergenic re-
gion between the MYB (MIM 189990) [12] and HBS1L
(MIM 612450) genes that resides on chromosome 6q22.3
[7, 13–15]. These genes have been identified by genome-
wide association or traditional linkage analysis approaches.
In addition, it has been previously reported that genetic
variants in the KLF1 (MIM 600599) gene are causative for
HPFH, in part by rendering the expression of BCL11A low
[16–18]. The identification of some of the direct transcrip-
tional regulatory regions within the β-like globin gene
cluster targeted by these transcription factors has been re-
ported [15, 19–21].
The extremely high variation of HbF levels observed in
carriers of the KLF1 p.K288X variant led us to further
examine other potential contributors to the fine-tuning
of the γ- to β-globin gene expression balance [22].
Whole transcriptome analysis performed on mRNA
from primary erythroid cultures revealed that expression
levels of ASF1B (MIM 609190), located in chromosome
19, close to the region that showed the highest LOD
scores when using multi-point parametric analysis at a
penetrance of 90% [16], were downregulated to 70% in
HPFH family members. ASF1B, anti-silencing function
1B histone chaperone gene, is a member of the evolu-
tionary conserved family of H3/H4 histone chaperone
proteins. In humans and mice, there are two paralogues
of the Asf1 protein in yeast, namely ASF1A (MIM
609189) and ASF1B [23–26]. Both ASF1A and ASF1B
participate in DNA synthesis-independent assembly of
histone H3.3 into chromatin [27]. However, ASF1A and
ASF1B are distinct in expression pattern and function.
While ASF1A is ubiquitously expressed, ASF1B is
expressed in highly proliferating tissues, and its expres-
sion levels decrease in terminally differentiated and qui-
escent cells [28]. It was described previously that ASF1B
and the histone H3.3 promote pancreatic β-cell prolifer-
ation in a synergistic manner [29]. The ASF1B protein is
the substrate of the tousled-like kinase family of cell
cycle-regulated kinases [30–32] and is thought to play a
key role in modulating the nucleosome structure of
chromatin by ensuring a constant supply of histones at
sites of nucleosome assembly [27], while interacting dir-
ectly with transcription regulators [23, 24, 33, 34].
ASF1B also cooperates with chromatin assembly factor 1
(CAF-1) to promote replication-dependent chromatin
assembly [35, 36], but it does not participate in
replication-independent nucleosome deposition medi-
ated by ASF1A and HIRA [28, 37]. Mouse-human inter-
species ASF1B protein identity is 91.6%.
In the present study, we have employed lentivirus-
mediated knockdown in primary human erythroblast
cultures and analyzed the Asf1b KO mice [38] to demon-
strate that ASF1B histone chaperone is functionally
linked to steady-state erythropoiesis. Our data shows
that loss of ASF1B compromises steady-state erythropoi-
esis with modest effects on the regulation of the β-like
globin genes.
Results
ASF1B is downregulated in human primary erythroid
progenitors carrying the p.K288X KLF1 variant
A SNP in the KLF1 gene resulting in p.K288X protein
variant, causative of the inherited HPFH in 10 out of 27
recruited members of a Maltese family, was reported
previously [16]. The identification of the point mutation
in the Maltese family was achieved through SNP linkage
analysis, which pointed to a region in chromosome
19p13.12-13 that showed the highest LOD scores when
using multi-point parametric analysis at a penetrance of
90% [16]. No evidence of linkage was observed to other
regions, including the HBB locus and the HPFH-linked
loci of chromosomes 2q33 and 6q22.3. However, HbF
levels ranged from ~ 3% to almost 20%, suggesting other
contributing factors to the variation of HbF levels among
HPFH family members [16].
Examining in more detail the region in chromosome
19 that showed the highest LOD scores and the expres-
sion in erythroid primary cultures of the neighboring
genes in close proximity (GSE22109), we identified
ASF1B, which was found to be downregulated in HPFH
family members (Fig. 1a) [16]. As shown in Fig. 1a, and
as previously reported, KLF1 targets BCL11A, CD44
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(MIM 107269), E2F2 (MIM 600426), E2F4 (MIM
600659), and HBB (MIM 141900), were significantly
downregulated, and the γ-globin versus total γ+β-globin
expression ratio was increased in primary erythroid cells
derived from HPFH individuals [16]. We confirmed that
ASF1B mRNA levels were significantly reduced to 70%
in HPFH family members presenting with the highest
HbF levels. Since we could not exclude that the tran-
scription of ASF1B is dependent on KLF1 or BCL11A
activities, we performed knockdown of either KLF1 or
BCL11A in healthy human primary erythroid progeni-
tors and analyzed the ASF1B expression levels accord-
ingly. BCL11A downregulation did not affect the
expression of ASF1B at all, while KLF1 knockdown re-
sulted in a small reduction of ASF1B expression which
did not reach statistical significance (Fig. 1b). This sug-
gests that the significant reduction of ASF1B expression
levels in primary erythroid cells cultured from the HPFH
family members might be partially, but not exclusively,
due to transcription regulation by KLF1.
Knockdown of ASF1B in human primary erythroid cells
induces γ-globin expression
To functionally assess the consequences of ASF1B down-
regulation on human β-globin gene expression, we per-
formed knockdown experiments on primary human
erythroblasts derived from healthy donors. We used three
shRNA lentiviral constructs against ASF1B, of which two
(#23 and #24, Supplementary Table 1) resulted in efficient
knockdown as measured by RT-qPCR. Therefore, we used
those two for further analysis. We included BCL11A and
KLF1 lentiviral shRNA-transduced cells as the positive
controls for γ-globin reactivation and a non-specific
scrambled (Scr) shRNA as the negative control. After len-
tiviral transduction and 24h selection with puromycin,
cells were induced to differentiate (+Epo and holo-
transferrin), and after 24 h, cells were collected for ana-
lysis. We confirmed the shRNA-mediated downregulation
of BCL11A, KLF1, and ASF1B transcripts by RT-qPCR
(Fig. 2a). We then investigated the impact of ASF1B
knockdown on BCL11A and KLF1 expression. We found
Fig. 1 ASF1B is downregulated in the primary erythroid progenitors carrying the p.K288X KLF1 variant. a Expression analysis from publicly
available microarray data (GSE22109) [16] derived from cultured primary erythroid cells (HEPs) of Maltese family members with HPFH (green bars,
n = 3) and normal family members (gray bars, n = 3). Family members with HPFH display reduction of BCL11A, ASF1B, E2F2, E2F4, CD44, and HBB
and increased HBG/(HBB+HBG) ratio. Mean and standard deviation are depicted. T test p values are indicated. *p < 0.05; **p < 0.005; ***p <
0.0005. b Analysis of KLF1, BCL11A, and ASF1B expression by RT-qPCR on HEPs derived from buffy coats from healthy individuals and transduced
with shRNA lentiviruses targeting KLF1 and BCL11A. Knockdown of either factor does not influence significantly the ASF1B expression. Expression
levels are normalized setting expression levels of mock knockdown controls at 100. Mean and standard deviation are depicted. Shadowed box at
100 corresponds to the expression levels in mock knockdown controls. T test p values are indicated. *p < 0.05; **p < 0.005; ***p < 0.0005
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that knockdown of ASF1B did not affect the expression of
KLF1 and BCL11A levels significantly (Fig. 2b). It is
known that one of the principal targets of KLF1 is the
HBB gene (encoding β-globin) [39, 40], and we could ver-
ify that by knocking down the KLF1 gene expression (Fig.
2c). Indirect downregulation of HBB gene transcription,
due to the upregulation of γ-globin expression, has been
reported upon BCL11A knockdown in human proerythro-
blasts [41]. We also observed this in our human erythroid
cultures (Fig. 2d). In contrast, ASF1B knockdown did not
reduce the levels of HBB mRNA expression (Fig. 2c). HBA
expression levels were also not altered significantly in the
ASF1B KD experiments (Fig. 2c). When measuring
hemoglobin composition from the lentiviral-transduced
Fig. 2 Knockdown of ASF1B in human primary erythroid cells induces γ-globin expression. a Expression analysis by RT-qPCR of ASF1B, BCL11A,
and KLF1 (last two taken from Fig. 1b) on shRNA lentivirus-transduced HEP cultures. Expression levels are normalized setting expression levels of
mock knockdown controls (Scr) at 100. Mean and standard deviation are depicted. Shadowed box at 100 corresponds to the expression levels in
mock knockdown controls. T test p values are indicated. b The expression of BCL11A and KLF1 is not significantly affected in ASF1B knockdown
HEPs as analyzed by RT-qPCR. Expression levels are normalized setting expression levels of mock knockdown controls (Scr) at 100. Mean and
standard deviation are depicted. Shadowed box at 100 corresponds to the expression levels in mock knockdown controls. T test p values are
indicated. c HBB and HBA expression analysis by RT-qPCR. Knockdown of either KLF1 or BCL11A has an effect on HBB expression, whereas ASF1B
knockdown does not, while overall, HBA expression is not affected. Expression levels are normalized setting expression levels of mock knockdown
controls (Scr) at 100. Mean and standard deviation are depicted. Shadowed box at 100 corresponds to the expression levels in mock knockdown
controls. T test p values are indicated. d RT-qPCR of HBG expression and HPLC analysis of hemoglobin composition show the increase in HbF
after knockdown of ASF1B in HEPs. Values are normalized to those measured in mock knockdown controls (Scr). Mean and standard deviation are
depicted. Shadowed box at 100 corresponds to the expression levels in mock knockdown controls. T test p values are indicated
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HEPs by qRT-PCR and HPLC, we observed that ASF1B
knockdown increased γ-globin expression, as shown by
the percentage of HbF of total hemoglobin in the samples
(Fig. 2d).
Asf1b KO mice display mild dyserythropoiesis
To investigate the potential contribution of ASF1B in
erythropoiesis and globin gene expression regulation, we
set out to study these processes in Asf1b knockout (KO)
mice. Complete blood count was performed on blood
samples from adult Asf1b KO mice and wild-type (WT)
littermates (Fig. 3a). Interestingly, Asf1b KO mice
present with a reduced red blood cell (RBC) count (8.62
versus 9.34 × 109 cells/ml; p < 0.05), an increased mean
cell volume (MCV 49.15 versus 46.10 fL; p < 107), and
an increased mean corpuscular hemoglobin (MCH 15.62
versus 14.80; p > 10−6), suggestive of compensatory
anemia. Their spleen was significantly enlarged (116.91
versus 90.20mg; p < 0.05), supporting this notion, consid-
ering the increased tendency of the body size of Asf1b KO
mice that did not reach statistical significance (Table 1).
We next set out to study the erythroid compartment
in the bone marrow and spleen of Asf1b KO mice (Fig.
3b, c). The bone marrow presented an accumulation of
early erythroid progenitors (CD71+Ter119neg) and a sig-
nificant reduction of the Ter119 positive cells, “A”
(CD71+FSChigh), “B” (CD71+FSClow), and “C” (CD71negF-
SClow) corresponding to more mature erythroid cells
(Fig. 3b, bar graph), based on the gating strategy by
Socolovsky [42]. When the megakaryocyte-erythroid-
progenitor (MEP) fraction was analyzed, we observed an
increase of these progenitors in Asf1b KO bone marrow
(Fig. 3b, dot plot). Analysis of the splenic erythroid
compartment revealed a significant increase of early
erythroid progenitors (proerythroblasts; CD71+Ter119-
neg), accompanied by a significant reduction of the more
mature cells, specially the population “C,” indicative of
moderate stress erythropoiesis (Fig. 3c). Altogether,
these data suggest that Asf1b KO mice present with mild
dyserythropoiesis and have engaged stress erythropoiesis
in the spleen.
Persistence of embryonic globin expression in adult
Asf1b KO mice
We next set out to analyze the expression of the β-like
globin genes in the blood, bone marrow, and spleen of
Asf1b KO mice and WT littermates. In mice, the devel-
opmental pattern of β-like globin gene expression is
marked by the expression of εy and βh1 in the embry-
onic stage, which is replaced by βmaj + βmin at the fetal
stage. RT-qPCR revealed significant upregulation of the
expression of εy-globin in the blood and bone marrow,
with a modest upregulation in the spleen which did not
reach statistical significance (Fig. 4). The upregulation of
εy-globin hemoglobin occurred without major alter-
ations in the expression levels of other embryonic
globins, i.e., βh1- and ζ-globin. A significant decrease, al-
though very mild, was identified in the bone marrow in
the total amount of β-globin expression compared to the
total amount of α-globin (Fig. 4b). This imbalance was
not detected in the blood of Asf1b KO mice (Fig. 4a).
This suggests that the normal α/β-globin ratio is re-
stored via a post-transcriptional mechanism, reminiscent
of erythropoiesis in individuals with thalassemia trait.
Thereof, we conclude that the increased expression of
εy-globin is not due to hampered expression of the other
globins. Collectively, these data indicate that although
not to the same extent as it occurs when knocking down
BCL11A (direct regulator) or KLF1 (indirect regulator
via BCL11A and HBB), lower expression levels of ASF1B
promote γ-globin expression, apparently without redu-
cing HBB gene expression. Our data show that ASF1B
loss of function in mice causes mild dyserythropoiesis
with the persistence of εy globin in adult hematopoietic
tissues, and thus supporting the notion that the imbal-
ance of β-like globin expression might be due to dysreg-
ulated erythroid differentiation, rather than to a direct
role of ASF1B in globin switching.
Discussion
In this study, we report on the role of ASF1B in erythro-
poiesis and globin gene expression.
ASF1B is known to function as a histone chaperone
protein important in chromatin remodeling [27] and nu-
cleosome assembly and disassembly, and when knocked
down, it is also known to influence gene expression [43].
It has been recently reported that ASF1B might play a
role in epigenetic reprogramming [44, 45], and further-
more, in alternative telomere lengthening [46]. However,
the complete spectrum of ASF1B functions has not yet
been asserted, and especially interesting is the reported
cooperation between ASF1B and general transcription
factors such as the TFIID [24, 33]. Microarray analysis
on erythroid cells from a family carrying KLF1 p.K288X
variant leading to HPFH showed that family members
with high HbF levels had reduced ASF1B gene expres-
sion levels compared to family members with normal
(low) HbF levels. We studied the possibility of KLF1 dir-
ectly regulating ASF1B expression by performing knock-
down experiments on primary HEPs. However, we did
not observe significant downregulation of ASF1B upon
KLF1 knockdown, possibly due to the short-term nature
of the knockdown assays. It has been reported that
ASF1B gene expression is regulated by E2F factors [47,
48]. Since E2F2 and E2F4 are direct targets of KLF1, and
also downregulated in HPFH family members (Fig. 1a),
we cannot exclude an indirect contribution of the KLF1
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Fig. 3 Asf1b KO mice display mild dyserythropoiesis. a Complete blood count of blood samples from Asf1b KO mice and WT littermates. The red
blood cell (RBC) counts, the mean corpuscular volume (MCV), and mean corpuscular hemoglobin (MCH) are depicted on individual animals. The
black bar is the mean. T test p value is indicated. b Left, bar graph depicting the flow cytometry analysis of the erythroid compartment in the
bone marrow of Asf1b KO and WT littermates following the gating strategy of Socolovsky [42]. Right, dot plot depicting the basal percentage of
megakaryocyte-erythroid progenitors in the bone marrow of Asf1B KO mice and WT littermates. The black bar is the mean. T test p value is
indicated. c Bar graph depicting the flow cytometry analysis of the erythroid compartment in the spleen of Asf1b KO and WT littermates
following the gating strategy of Socolovsky [42]
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Table 1 Body and spleen weight of Asf1b KO mice and WT littermates. Mice included in this analysis are female littermates from
heterozygous crossings. The body weight, spleen weight, and spleen weight/body weight ratio are shown. The mean and standard
deviation are indicated. T test p values are given
Genotype Body weight (g) Spleen weight (mg) Spleen/body weight
WT (N = 10) 25.93 ± 2.67 90.20 ± 13.54 3.50 ± 0.54
Asf1b KO (N = 8) 28.38 ± 4.26 124.13 ± 28.09 4.56 ± 1.77
p value NS < 0.05 NS
NS not significant
Fig. 4 Persistence of embryonic globin expression in adult Asf1b KO mice. Expression analysis by RT-qPCR of β-like and α-like globin genes in the
blood (a), bone marrow (b), and spleen (c) samples from Asf1b KO mice and WT littermates. Ratios of relative fold enrichment (RFE) of a given β-
like or α-like globin versus total β- or α-globin, respectively, are depicted. Mean and standard deviation are represented, and T test p values are
indicated. *p < 0.05; ***p < 0.0005
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variant to the downregulation of ASF1B expression via
E2F2/E2F4.
Importantly, the microarray data shows a significant de-
crease of HBB gene transcription in those family members
with high HbF levels, similarly to what has been docu-
mented for cis-acting genetic variants or SNPs in the HBB
gene promoter CACCC box (see also http://globin.bx.psu.
edu/hbvar) [20, 21] to which KLF1 binds. In addition, γ-
globin gene expression is upregulated. Thus, it is the bal-
ance β- versus γ-globin expression that results in the high
percentage of HbF, in this case, by directly affecting the
expression of γ- and β-globin in an opposite manner.
Since microarrays are not suitable for measuring glo-
bin expression due to saturation of the probe sets, we
confirmed these dynamics with RT-qPCR analysis in
knockdown assays. The results of knockdown experi-
ments of KLF1 and BCL11A in adult erythroid progeni-
tors from healthy donors agreed with such an
observation, i.e., increase of HbF levels compared to the
control shRNA, with accompanying decrease in β-globin
expression (Fig. 2). This effect on β-globin expression
downregulation has been seen in single and compound
knockout mouse models for Klf1 and Bcl11a [49]. Inter-
estingly, knockdown of ASF1B resulted in an increase of
HbF, without significantly altering KLF1, BCL11A, or β-
globin expression (Fig. 2).
It has been recently reported that KLF1 recruits histone
chaperones HIRA and ASF1A to maintain an open β-
globin locus and that this recruitment is necessary for
proper β-globin transcription [40]. Although ASF1A and
ASF1B are paralogues, it is known that ASF1B does not co-
operate with the ASF1A/HIRA complex and that it per-
forms separate actions on nucleosome assembly [28, 37].
Our results are therefore in agreement with this notion,
since depletion of ASF1B did not affect β-globin expression,
neither in the Asf1b KO mouse model, nor in human eryth-
roid progenitors where ASF1B had been knocked down.
The analogy between KLF1 and ASF1B goes further re-
garding general erythropoiesis. It has been recognized that
a special case of a genetic variant of KLF1 is causative of
congenital dyserythropoietic anemia (CDA) variant (type
IV) in addition to the accompanying HPFH already re-
ported. Interestingly, the two genes involved in the devel-
opment of CDA type I are CDAN1 and C15ORF41, both
of which have been reported to physically interact with
ASF1B [50–55]. This suggests that shared functions by the
interacting proteins ASF1B, CDAN1, and C15ORF41
might be crucial during erythropoiesis and for β-like glo-
bin expression regulation.
Indeed, loss of function studies in Asf1b KO mice
revealed mild dyserythropoiesis and persistence of εy-
globin expression in adult hematopoietic tissues, without
altering the expression levels of other β-like globins.
While there was a statistically significant reduction of
the total β-like globins compared to α-globins, this was
only identified in the bone marrow, and it was very mild.
These results, which are in total concordance with our
observations in human cellular models of erythropoiesis,
indicate that ASF1B fine-tunes erythropoiesis in vivo.
It has been suggested that ASF1B deficiency results in
cell cycle defects due to impaired nucleosome assembly
[26, 35, 36, 54, 56]. In this regard, a defective shorter cell
cycle during erythropoiesis might result in the produc-
tion of immature, “skipping division” erythroid cells,
which contain higher levels of HbF. In fact, hemolytic
treatment in mice or baboons results in an increase of
erythroid cells containing fetal/embryonic globin [57,
58]. It has also been described that ASF1B interacts with
TFIID [24]. Such interactions involving also transcrip-
tion regulators, which we have previously shown to be
important for mouse erythropoiesis [59], could have a
major impact in the coordination between chromatin re-
modeling, chromatin accessibility, and transcription
regulation, and affect consequently gene expression of
the β-like globin genes [24, 33]. Experimental evidence
of how ASF1B is involved in these processes (cell cycle/
replication, transcription, epigenetic regulation) and its
role in the molecular mechanism behind the transcrip-
tion/silencing of the γ-globin genes is missing from our
work. Identification of interactors of ASF1B by immuno-
precipitation and mass spectrometry as well as cell cycle
analysis in erythroid cells should contribute in this direc-
tion and should be the subject of future studies.
Conclusions
In essence, our data indicate that ASF1B cooperates to
adult steady-state erythroid differentiation and, most
probably associated with this mechanism, it has an
accessory function in the silencing of the embryonic glo-
bin genes. At present, the exact mechanism by which
ASF1B exerts its function related to globin gene expres-
sion remains unclear, and further experiments should
focus on the molecular characterization of the protein.
Methods
Mice
Asf1b knockout mice were generated as described previ-
ously [38]. All animal studies were performed in compli-
ance with the European Community regulation for
laboratory animal care and use (Directive 2010/63/UE).
The mouse facility of the CEA at Fontenay-aux-Roses
received the agreement delivered by the French Ministry
of Agriculture (no. D92032-02). Mice were sacrificed by
cervical dislocation. All efforts were made to minimize
animal stress and suffering. Mice were housed in con-
trolled 12-h light:12-h dark conditions (lights on from
08:00 to 20:00 h) and were supplied with commercial
food and tap water ad libitum. The colony of mice was
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maintained by breeding heterozygous mice, so knockout
mice could be compared with wild-type littermates and
all mating pairs in the same mouse facility. Mouse sam-
ples were collected for analysis at 3–8 months of age.
Flow cytometry
Bone marrow and spleen single-cell suspensions were la-
beled with respective antibody cocktails. For the analysis
of the erythroid compartment, CD71-APCCy7 and
Ter119-Pacific Blue antibodies were used (BD), and suc-
cessive stages of erythroid maturation were calculated as
previously described [42]. For MEP analyses, the BM cells
were first treated with a 0.75% NH4Cl solution (Sigma-Al-
drich, St. Louis, MO, USA) to lyse red blood cells and la-
beled with a biotinylated lineage cell detection cocktail
(Miltenyi Biotec) and revealed by streptavidineFluor450
(eBioscience). The cells were then labeled with PE-
conjugated anti-CD34, APCCy7-conjugated anti-c-Kit,
APC-conjugated anti-Sca-1, and PECy7-conjugated anti-
CD16/32 (eBioscience) antibodies, and MEPs were identi-
fied as Lin−, Sca-1−, c-Kit+, CD16/32−, and CD34− [60].
At least 300,000 cells were acquired.
The cells were analyzed using a FACSCanto II and a
SORP LSRII (BD) equipped with blue (488 nm), violet
(405 nm), and red (638 nm) lasers. Data were analyzed
with the FlowJo software.
Cell cultures
Human erythroid progenitor cells (HEPs) were cultured as
described [16, 61] in the presence of recombinant human
Epo (Eprex, 1 U/ml), recombinant human SCF (100 ng/
ml), and dexamethasone (10−6M, Sigma) from processed
buffy coats of active blood donors (Sanquin Blood Bank),
according to the guidelines of the Declaration of Helsinki
and after approval of the local ethical committee. Cells
were cultured at 1.5–3 × 106/ml through daily dilutions or
medium replacement. Cells were counted with an elec-
tronic cell counter (CASY-1, Schärfe-System, Germany).
To induce terminal differentiation, cells were washed and
transferred to medium with recombinant human Epo
(Eprex, 10 U/ml) and a high concentration of iron-loaded
transferrin (Sigma, 0.5mg/ml). Cells were harvested for
further analysis (RNA extraction and HPLC) after 24 h in
the differentiation medium.
Transduction of human proerythroblasts with shRNA
lentiviral constructs
Lentivirus was produced by transient transfection of HEK
293T cells according to the standard protocols [16, 62].
Two days after transfection, the supernatant was collected,
filtered, and concentrated by centrifugation at 20k rpm for
2 h at 4 °C. HEPs cultured for 1 week from fresh buffy
coats from healthy volunteers (Sanquin Blood Supply) were
transduced in 24-well plates. We used 0.5 × 106 cells per
well and sufficient amounts of virus to transduce ~ 80% of
the cells at day 1. Puromycin (1 μg/ml final concentration)
was added to the cells at day 2, and the selection was per-
formed for 24 h. At day 3, cells were induced to differenti-
ate and were harvested at day 4 for RNA extraction and
HPLC analysis as described above. The clones from The
RNAi Consortium (TRC [63]; Sigma) used were as follows:
the non-target SHC002 vector (Scrambled “Scr” control;
SHC002: 5′-CAACAAGATGAAGAGCACCAA-3′), KLF1
shRNA clone TRCN0000016276, [16] BCL11A shRNA
clone TRCN0000033449 (validated by us), and ASF1B
shRNA clones TRCN0000074225, TRCN0000074226, and
TRCN0000074227, of which only the last two gave signifi-
cant knockdown. Sequences are listed in Supplementary
Table 1.
High-performance liquid chromatography
Separation and quantification of Hb fractions were per-
formed by high-performance cation-exchange liquid
chromatography (CE-HPLC) on Waters Alliance 2690
equipment (Waters, Milford, MA, USA). The protocol
consisted of a 30-min elution over a combined 20–200
mM NaCl and pH 7.0–6.6 gradient in 20mM BisTris/
HCl, 2 mM KCN. The column, a PolyCAT A 100/4.6-
mm, 3-μm, 1500-Å column, was purchased from PolyLC
(Columbia, MD, USA) [64].
RNA extraction and RT-qPCR analysis
Total RNA (1 μg) from each harvested erythroid cell
sample after extraction by TRIzol (Invitrogen) was con-
verted to cDNA with SuperScript II reverse transcriptase
according to the manufacturer’s instructions (Invitrogen,
Paisley, UK). For mouse tissues, the RNeasy Mini Kit
(Qiagen) was used to isolate total RNA according to the
manufacturer’s instructions. Primers used to amplify
BCL11A, ASF1B, E2F2, E2F4, HBB, and HBG1/HBG2
human genes and mouse globin genes plus controls are
listed in Supplementary Table 1.
All amplifications took place with SYBR Green PCR
Master Mix (Applied Biosystems). RT-qPCR was per-
formed on the Bio-Rad Optical IQ Thermal Cycler (Bio-
Rad) under the following conditions: 50 °C for 2 min and
95 °C for 10 min, followed by 45 cycles of 95 °C for 30 s
and 62 °C for 30 s. All reactions were performed in
triplicate.
Target gene expression was normalized to GAPDH
expression. Gene expression levels were calculated with
the 2(−DeltaDeltaC(T)) method [65].
Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s40246-020-00283-3.
Additional file 1. List of shRNA clones and primer sets used.
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